Gilead Sciences Earnings
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Gilead Sciences earnings summary
In its most recent report on Oct 29, 2026 (Sep/2026), GILD posted EPS of $2.47 versus the $2.17 consensus estimate, a positive surprise of 13.8%. Revenue for the quarter was $8.30 billion. Quarterly EPS is up 1.6% from the same quarter a year earlier.
Across the last 16 reports, GILD shares moved an average of 2.3% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.
Summary generated from market data by MetaCap's automated system. Methodology
GILD earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Oct 29, 2026 | $2.17 | $2.47 | +13.8% | -2.2% |
| Aug 6, 2026 | — | $-8.45 | — | +3.9% |
| May 7, 2026 | — | $1.61 | — | -1.3% |
| Feb 24, 2026 | — | $1.75 | — | -3.4% |
| Nov 7, 2025 | — | $2.43 | — | +5.2% |
| Aug 7, 2025 | — | $1.56 | — | -0.9% |
| May 7, 2025 | — | $1.04 | — | +5.8% |
| Feb 28, 2025 | — | $1.43 | — | +2.7% |
| Nov 12, 2024 | — | $1.00 | — | +2.0% |
| Aug 8, 2024 | — | $1.29 | — | +0.2% |
| May 8, 2024 | — | $-3.34 | — | +2.7% |
| Feb 23, 2024 | — | $1.14 | — | -1.7% |
| Nov 7, 2023 | — | $1.73 | — | -0.6% |
| Aug 4, 2023 | — | $0.83 | — | +1.7% |
| May 3, 2023 | — | $0.80 | — | -2.0% |
| Feb 22, 2023 | — | $1.29 | — | +0.5% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.